RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00023610.xml
Drug Res (Stuttg) 2014; 64(S 01): S24
DOI: 10.1055/s-0033-1358038
DOI: 10.1055/s-0033-1358038
Symposium der Paul-Martini-Stiftung
M/XDR-Tuberculosis: Therapy as Prevention
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
25. November 2014 (online)

As the incidence of tuberculosis (TB) has been globally declining over the past decades the World Health Organization (WHO) is now proposing the elimination of TB in Europe. However, in the absence of an effective vaccine for the prevention of TB, elimination of TB will not be possible in the near future due to the emergence of drug-resistant strains of Mycobacterium tuberculosis. Forty-four percent of all patients identified with multidrug-resistant or extensively drug-resistant tuberculosis (MDR-TB, XDR-TB) worldwide live in the European Region of the WHO. Management and prognosis of patients with M/XDR-TB is dramatically different from patients with pan drug-susceptible TB in several ways.